TLR4 and metabolic disease: Our findings confirm the previous opinions that the TLR4 signaling pathway in hypothalamus is an attractive target for treatment of obese conditions, and further suggest that ARC-restricted TLR4 knockdown is a potential strategy to combat metabolic disorders associated with obesity.